Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
July 2017

Valbenazine (Ingrezza): The First Drug Approved to Treat TD
Valbenazine (Ingrezza), an inhibitor of vesicular monoamine transporter 2 (VMAT2), is the first medication approved by the FDA to treat tardive dyskinesia.

A Dietary Supplement to Reduce the Risk of Postpartum Depression?
In a small, open-label trial, a dietary supplement decreased the propensity for sadness in postpartum women.

Pimavanserin (Nuplazid) for Parkinson Disease Psychosis
Pimavanserin (Nuplazid), a new molecular entity, is the first drug approved by the FDA to treat Parkinson disease psychosis.

In Brief
Review Finds that Dietary Supplements and Special Diets Do Not Improve Autism Symptoms; Aerobic Exercise Improves Executive Function in Adults with Vascular Cognitive Impairment

Don't Forget Clozapine
A recent survey found that US residents are hesitant to prescribe clozapine (Clozaril and others) for patients with schizophrenia, citing fear of side effects and lack of sufficient training on how to properly prescribe and monitor clozapine treatment.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.